Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

Roman Perez-Soler, B. S. Glisson, J. S. Lee, F. V. Fossella, W. K. Murphy, D. M. Shin, W. K. Hong

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Purpose: This study was designed to assess the antitumor activity of topotecan (TPT) in patients with small-cell lung cancer (SCLC) refractory to etoposide. Patients and Methods: Refractoriness to etoposide was defined as lack of response to etoposide-containing frontline therapy, or progression during or within 3 months of the last dose of etoposide-containing frontline or second-line therapy. Other eligibility criteria were presence of measurable disease, Zubrod scale performance status (PS) ≤ 2, ≤ two prior chemotherapy regimens, and adequate renal and liver function. TPT was administered at a dose of 1.25 mg/m2/d for 5 days over 30 minutes every 21 days. Results: Thirty-two patients were registered, of whom 28 are fully assessable. All patients had been treated with frontline etoposide and cisplatin. Three patients (11%) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) and two (7%) achieved a minor response; five patients (17%) had stable disease and 18 (65%) had progressive disease. One of the three patients who achieved a PR had failed to respond to frontline cisplatin and etoposide. The overall median survival duration was 20 weeks. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 70% and 31% of courses administered, respectively. No grade 3 to 4 nonhematological toxicities were observed. Grade 1 or 2 nonhematological toxicities (in percentage of patients) consisted of nausea (41%, 8%) and vomiting (25%, 11%), and alopecia (100%). Conclusion: TPT at the dose and schedule used has modest antitumor activity in SCLC patients refractory to etoposide and cisplatin, which indicates that clinical resistance to the topoisomerase II poison etoposide does not confer cross-sensitivity to the topoisomerase I poison TPT. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.

Original languageEnglish (US)
Pages (from-to)2785-2790
Number of pages6
JournalJournal of Clinical Oncology
Volume14
Issue number10
StatePublished - 1996
Externally publishedYes

Fingerprint

Topotecan
Type I DNA Topoisomerase
Poisons
Small Cell Lung Carcinoma
Etoposide
Cisplatin
Therapeutics
Type II DNA Topoisomerase
Agranulocytosis
Alopecia
Nausea
Vomiting
Appointments and Schedules
Kidney
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Perez-Soler, R., Glisson, B. S., Lee, J. S., Fossella, F. V., Murphy, W. K., Shin, D. M., & Hong, W. K. (1996). Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of Clinical Oncology, 14(10), 2785-2790.

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. / Perez-Soler, Roman; Glisson, B. S.; Lee, J. S.; Fossella, F. V.; Murphy, W. K.; Shin, D. M.; Hong, W. K.

In: Journal of Clinical Oncology, Vol. 14, No. 10, 1996, p. 2785-2790.

Research output: Contribution to journalArticle

Perez-Soler, Roman ; Glisson, B. S. ; Lee, J. S. ; Fossella, F. V. ; Murphy, W. K. ; Shin, D. M. ; Hong, W. K. / Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 10. pp. 2785-2790.
@article{34ce627faded4e35b91f1d6c2f5b3bb5,
title = "Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan",
abstract = "Purpose: This study was designed to assess the antitumor activity of topotecan (TPT) in patients with small-cell lung cancer (SCLC) refractory to etoposide. Patients and Methods: Refractoriness to etoposide was defined as lack of response to etoposide-containing frontline therapy, or progression during or within 3 months of the last dose of etoposide-containing frontline or second-line therapy. Other eligibility criteria were presence of measurable disease, Zubrod scale performance status (PS) ≤ 2, ≤ two prior chemotherapy regimens, and adequate renal and liver function. TPT was administered at a dose of 1.25 mg/m2/d for 5 days over 30 minutes every 21 days. Results: Thirty-two patients were registered, of whom 28 are fully assessable. All patients had been treated with frontline etoposide and cisplatin. Three patients (11{\%}) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) and two (7{\%}) achieved a minor response; five patients (17{\%}) had stable disease and 18 (65{\%}) had progressive disease. One of the three patients who achieved a PR had failed to respond to frontline cisplatin and etoposide. The overall median survival duration was 20 weeks. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 70{\%} and 31{\%} of courses administered, respectively. No grade 3 to 4 nonhematological toxicities were observed. Grade 1 or 2 nonhematological toxicities (in percentage of patients) consisted of nausea (41{\%}, 8{\%}) and vomiting (25{\%}, 11{\%}), and alopecia (100{\%}). Conclusion: TPT at the dose and schedule used has modest antitumor activity in SCLC patients refractory to etoposide and cisplatin, which indicates that clinical resistance to the topoisomerase II poison etoposide does not confer cross-sensitivity to the topoisomerase I poison TPT. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.",
author = "Roman Perez-Soler and Glisson, {B. S.} and Lee, {J. S.} and Fossella, {F. V.} and Murphy, {W. K.} and Shin, {D. M.} and Hong, {W. K.}",
year = "1996",
language = "English (US)",
volume = "14",
pages = "2785--2790",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

AU - Perez-Soler, Roman

AU - Glisson, B. S.

AU - Lee, J. S.

AU - Fossella, F. V.

AU - Murphy, W. K.

AU - Shin, D. M.

AU - Hong, W. K.

PY - 1996

Y1 - 1996

N2 - Purpose: This study was designed to assess the antitumor activity of topotecan (TPT) in patients with small-cell lung cancer (SCLC) refractory to etoposide. Patients and Methods: Refractoriness to etoposide was defined as lack of response to etoposide-containing frontline therapy, or progression during or within 3 months of the last dose of etoposide-containing frontline or second-line therapy. Other eligibility criteria were presence of measurable disease, Zubrod scale performance status (PS) ≤ 2, ≤ two prior chemotherapy regimens, and adequate renal and liver function. TPT was administered at a dose of 1.25 mg/m2/d for 5 days over 30 minutes every 21 days. Results: Thirty-two patients were registered, of whom 28 are fully assessable. All patients had been treated with frontline etoposide and cisplatin. Three patients (11%) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) and two (7%) achieved a minor response; five patients (17%) had stable disease and 18 (65%) had progressive disease. One of the three patients who achieved a PR had failed to respond to frontline cisplatin and etoposide. The overall median survival duration was 20 weeks. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 70% and 31% of courses administered, respectively. No grade 3 to 4 nonhematological toxicities were observed. Grade 1 or 2 nonhematological toxicities (in percentage of patients) consisted of nausea (41%, 8%) and vomiting (25%, 11%), and alopecia (100%). Conclusion: TPT at the dose and schedule used has modest antitumor activity in SCLC patients refractory to etoposide and cisplatin, which indicates that clinical resistance to the topoisomerase II poison etoposide does not confer cross-sensitivity to the topoisomerase I poison TPT. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.

AB - Purpose: This study was designed to assess the antitumor activity of topotecan (TPT) in patients with small-cell lung cancer (SCLC) refractory to etoposide. Patients and Methods: Refractoriness to etoposide was defined as lack of response to etoposide-containing frontline therapy, or progression during or within 3 months of the last dose of etoposide-containing frontline or second-line therapy. Other eligibility criteria were presence of measurable disease, Zubrod scale performance status (PS) ≤ 2, ≤ two prior chemotherapy regimens, and adequate renal and liver function. TPT was administered at a dose of 1.25 mg/m2/d for 5 days over 30 minutes every 21 days. Results: Thirty-two patients were registered, of whom 28 are fully assessable. All patients had been treated with frontline etoposide and cisplatin. Three patients (11%) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) and two (7%) achieved a minor response; five patients (17%) had stable disease and 18 (65%) had progressive disease. One of the three patients who achieved a PR had failed to respond to frontline cisplatin and etoposide. The overall median survival duration was 20 weeks. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 70% and 31% of courses administered, respectively. No grade 3 to 4 nonhematological toxicities were observed. Grade 1 or 2 nonhematological toxicities (in percentage of patients) consisted of nausea (41%, 8%) and vomiting (25%, 11%), and alopecia (100%). Conclusion: TPT at the dose and schedule used has modest antitumor activity in SCLC patients refractory to etoposide and cisplatin, which indicates that clinical resistance to the topoisomerase II poison etoposide does not confer cross-sensitivity to the topoisomerase I poison TPT. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0029758947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029758947&partnerID=8YFLogxK

M3 - Article

C2 - 8874340

AN - SCOPUS:0029758947

VL - 14

SP - 2785

EP - 2790

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -